CN101569706A - Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny - Google Patents
Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny Download PDFInfo
- Publication number
- CN101569706A CN101569706A CNA2008101056988A CN200810105698A CN101569706A CN 101569706 A CN101569706 A CN 101569706A CN A2008101056988 A CNA2008101056988 A CN A2008101056988A CN 200810105698 A CN200810105698 A CN 200810105698A CN 101569706 A CN101569706 A CN 101569706A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- hyperosteogeny
- radix
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by the hyperosteogeny, which comprises strychnos, radix aconiti, radix aconiti feri, arisaema cum bile, pinellia, euphorbia kansui, eupolyphaga, white grub, paris polyphylla smith, datura flower, brassica alba boiss, radix notoginseng, frankincense, myrrh, dragon's blood, cinnamon, asarum, borneol, camphor and the like. The pharmaceutical composition has the functions of promoting blood circulation to remove blood stasis, removing cold and food retention, and repairing anadesma and periosteum subcutaneous nodules to achieve blood circulation and recovery, and has remarkable curative effect of treating the hyperosteogeny and the neurothlipsis caused by the hyperosteogeny.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of the nerve compression that hyperosteogeny and hyperosteogeny cause.
Background technology
Hyperosteogeny is a kind of ancient disease, is a kind of pertinacious disease that is difficult to cure.Hyperosteogeny and articular degeneration can cause is invaded joint instability, the narrow or fissure of displacement; Can stimulation, pressuring nerve and blood vessel, can rub, stimulate that synovium of joint oozes out, edema, fine hair hypertrophy thicken, unsmooth etc.; Perhaps cause bone system fibrous tissue inflammatory edema, agglomerate adhesion or calcification etc. on every side; Perhaps cause disc tissue bulging, outstanding, cartilage comes off, the bone trabecula fracture, subside, even B﹠J distortion, dislocation etc., thereby clinical symptoms such as generation pain.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of the nerve compression that hyperosteogeny and hyperosteogeny cause.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Semen Strychni 30-90 weight portion Radix Aconiti 30-90 weight portion
Radix Aconiti Kusnezoffii 30-90 weight portion Rhizoma Arisaematis 25-75 weight portion
Rhizoma Pinelliae 25-75 weight portion Radix Kansui 15-45 weight portion
Eupolyphaga Seu Steleophaga 25-75 weight portion Holotrichia diomphalia Bates 15-45 weight portion
Rhizoma Paridis 25-75 weight portion Flos Daturae 25-75 weight portion
Semen Sinapis Albae 15-45 weight portion Radix Notoginseng 15-45 weight portion
Olibanum 25-65 weight portion Myrrha 25-65 weight portion
Sanguis Draxonis 15-45 weight portion Cortex Cinnamomi 15-45 weight portion
Herba Asari 25-65 weight portion Borneolum Syntheticum 10-30 weight portion
Camphora 25-75 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Semen Strychni 60 weight portion Radix Aconitis 60 weight portion Radix Aconiti Kusnezoffii 60 weight portions
The Rhizoma Arisaematis 50 weight portion Rhizoma Pinelliaes 50 weight portion Radix Kansuis 30 weight portions
Eupolyphaga Seu Steleophaga 50 weight portion Holotrichia diomphalia Batess 30 weight portion Rhizoma Paridis 50 weight portions
Flos Daturae 50 weight portion Semen Sinapis Albaes 30 weight portion Radix Notoginseng 30 weight portions
Olibanum 45 weight portion Myrrhas 45 weight portion Sanguis Draxonis 30 weight portions
Cortex Cinnamomi 30 weight portion Herba Asaris 45 weight portion Borneolum Syntheticums 20 weight portions
Camphora 50 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Semen Strychni 85 weight portion Radix Aconitis 85 weight portion Radix Aconiti Kusnezoffii 35 weight portions
The Rhizoma Arisaematis 30 weight portion Rhizoma Pinelliaes 70 weight portion Radix Kansuis 40 weight portions
Eupolyphaga Seu Steleophaga 30 weight portion Holotrichia diomphalia Batess 20 weight portion Rhizoma Paridis 70 weight portions
Flos Daturae 70 weight portion Semen Sinapis Albaes 20 weight portion Radix Notoginseng 20 weight portions
Olibanum 60 weight portion Myrrhas 60 weight portion Sanguis Draxonis 20 weight portions
Cortex Cinnamomi 20 weight portion Herba Asaris 60 weight portion Borneolum Syntheticums 25 weight portions
Camphora 30 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Semen Strychni 35 weight portion Radix Aconitis 35 weight portion Radix Aconiti Kusnezoffii 85 weight portions
The Rhizoma Arisaematis 70 weight portion Rhizoma Pinelliaes 30 weight portion Radix Kansuis 20 weight portions
Eupolyphaga Seu Steleophaga 70 weight portion Holotrichia diomphalia Batess 40 weight portion Rhizoma Paridis 30 weight portions
Flos Daturae 30 weight portion Semen Sinapis Albaes 40 weight portion Radix Notoginseng 40 weight portions
Olibanum 30 weight portion Myrrhas 30 weight portion Sanguis Draxonis 40 weight portions
Cortex Cinnamomi 40 weight portion Herba Asaris 30 weight portion Borneolum Syntheticums 15 weight portions
Camphora 70 weight portions.
Pharmaceutical composition of the present invention can also add Moschus 0.5-1.5 weight portion on the basis of above-mentioned 19 flavor crude drug, described Moschus is preferably: Moschus 1.0 weight portions, Moschus 0.7 weight portion or Moschus 1.3 weight portions.
Wherein, described Semen Strychni is preferably Semen Strychni, Radix Aconiti is preferably Radix Aconiti, and Radix Aconiti Kusnezoffii is preferably Radix Aconiti Kusnezoffii, and Rhizoma Arisaematis is preferably Rhizoma Arisaematis, the Rhizoma Pinelliae is preferably Rhizoma Pinelliae, Radix Kansui is preferably given birth to Radix Kansui, and Semen Sinapis Albae is preferably Semen Sinapis Albae, and Olibanum is preferably Olibanum, Myrrha is preferably Myrrha, and Radix Notoginseng is preferably Radix Notoginseng powder.
Pharmaceutical composition of the present invention, the conventional adjuvant that adds is pharmaceutically made any dosage form of clinical acceptance, as emplastrum, ointment, liniment, powder or spray.
Pharmaceutical composition of the present invention has promoting blood circulation to remove blood stasis, cold removing removing food stagnancy, repairs fascia, the periosteum subcutaneous nodule reaches the effect that the blood common fault heals, and the nerve compression that treatment is caused by hyperosteogeny and hyperosteogeny has significant curative effect.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example:
1, clinical data, diagnostic criteria
Nerve compression case 46 examples that clinical treatment hyperosteogeny of the present invention and hyperosteogeny cause, male 30 examples, women 16 examples obtain promising result.
2, preparation method: pharmaceutical composition of the present invention technology is routinely made unguentum or powder;
3, criterion of therapeutical effect:
Clinical cure: clinical symptom disappearance;
Produce effects: clinical symptoms all disappears, and routine work and life are not had obviously influence;
Effectively: clinical symptoms takes a turn for the better, and is influential but little to routine work and life;
Invalid: clinical symptoms does not have improvement or increases the weight of.
4, therapeutic outcome:
The present invention treats 46 routine patient's curative effect statistics: produce effects: 10 examples, account for 22%, effectively: 32 examples, account for 70%, invalid: 4 examples account for 8%.
5, model case:
Case 1, amyotrophy (osteomyelitis): Zhang, the woman, 68 years old, the lower limb hip was carefully thin, legs and feet (pinprick the is burning hot does not know) foot of losing consciousness turns up, the absent-mindedness of muscle arteries and veins can not walked, uses medicine composite for curing one and a half months of the present invention after, can oneself hold up rod to walk.
Case 2, osteomalacia: finish certain, man, 12 years old, three west of a river Yang Zhuan people, medical history: this person began transfusion in seven years old, and two, three days are once, headache, feeling of fullness in the head, dizziness, temple distending pain, and health is soft, behind two first quarter moons of here treatment, all diseases are eliminated, and after 1 year, follow up a case by regular visits to normal.
Case 3, old lumbar vertebra fracture: Korea Spro, woman, 50 years old, people from Qingdao is before 3 years, because of traumatic injury by bike, 3 wheat harvesting periods of having a rest at home, stiff, can only couch and pain, go the civilian hospital diagnosis and treatment, accuse it treating, through seeking the doctor in many ways, come here to go to a doctor, on March 18th, 2005 the X sheet: pulmonary, kidney district dampen has the stasis of blood to stagnate; Thoracic vertebra, many places, spinous process of lumbar vertebra position hypertrophy; The lumbar vertebra dislocation, fracture disconnects, and dizzy, Gastric Diseases by Spraying appear in the calcification demoulding.On April 10th, 2007 can squat down to April 11, dizzy disappearance on April 12, and the reduction of the fracture on April 23, Gastric Diseases by Spraying are eliminated, and May 15, the limb function exercise was done chores, and stopped the power work, and recovery from illness is left hospital.
Case 4, spondylitis merge osteomyelitis: Yin, and the woman, 18 years old, the Yan Zhuan Ziren, readme: lumbago, can not bend over menoxenia for many years; Symptom: thoracic vertebra; Before and after obviously fall in to the ossa thoracis joint, front and back displacements, lossless to the lumbar vertebra osteodynia, bone shape changes, spinal cord cavity (slightly) bone is tetanic, thoracic cavity expansion, but body can uprightly and not bend, the back of the body is carried on the back; In many ways it is invalid to seek medical advice, and examines upon somebody's introduction, treats half wheat harvesting period, and symptom is eliminated, locate as bending over, and a month hands, the menstruation of family members' announcement is also normal.
Case 5, breast expectorant pain: the Wang, the woman, 46 years old, the Yan Zhuan Ziren, symptom: lumbago, the chest distension is breathed oppressiveness, breathes hard, and back of the body rib flesh has the sound, and fascia, muscle are torn sound; The damage of shoulder joint periosteum synovial bursa, bone rings big especially, and the real chamber of expectorant resets, and back of the body rib point is pressed no sound, tears sound, and hyperosteogeny melts, and treats wheat harvesting period recovery from illness through here.
Case 6, bone tuberculosis: Song Zhuanren, woman, Wang, 40 years old, left elbow joint: 1, ulna bone hypertrophy 3cm * 1cm; 2, radius: bone integral body swells, the distressed pain of bone drill, and bone is slightly downright bad; 3, self-induction blood is not down walked to ancon, and upper arm separates with the forearm self-induction.The elbow joint softness is as dislocation.Treat recovery from illness in more than 20 day through here.
Case 7: the Wang, the man, 66 years old, the facial hemiparalysis hemiplegia, western medical treatment is invalid after eight days, and three times repeatedly, rise because of angry: The corners of one's mouth were droping two days, increases the weight of shock then: facial hemiparalysis, slurred speech, hemiplegia, arm enlargement; Can not hold the thing walking.Here treatment afterwards, usefulness pharmaceutical composition plaster of the present invention correcting deflection after 20 days, language is still clear, and hemiplegia is hand steered rod walking after 10 days.These human therapy two wheat harvesting periods now can walking freely, and it is steady fast to walk, and it is clear that hands can have been held the story speech, can do physical labor.
Following embodiment all can realize the described effect of above-mentioned experimental example
The specific embodiment
Embodiment 1: emplastrum
Semen Strychni 60kg Radix Aconiti 60kg Radix Aconiti Kusnezoffii 60kg
Rhizoma Arisaematis 50kg Rhizoma Pinelliae 50kg Radix Kansui 30kg
Eupolyphaga Seu Steleophaga 50kg Holotrichia diomphalia Bates 30kg Rhizoma Paridis 50kg
Flos Daturae 50kg Semen Sinapis Albae 30kg Radix Notoginseng 30kg
Olibanum 45kg Myrrha 45kg Sanguis Draxonis 30kg
Cortex Cinnamomi 30kg Herba Asari 45kg Borneolum Syntheticum 20kg
Camphora 50kg
Said medicine technology routinely adds conventional adjuvant and makes emplastrum.
Embodiment 2: ointment
Semen Strychni 85kg Radix Aconiti 85kg Radix Aconiti Kusnezoffii 35kg
Rhizoma Arisaematis 30kg Rhizoma Pinelliae 70kg Radix Kansui 40kg
Eupolyphaga Seu Steleophaga 30kg Holotrichia diomphalia Bates 20kg Rhizoma Paridis 70kg
Flos Daturae 70kg Semen Sinapis Albae 20kg Radix Notoginseng 20kg
Olibanum 60kg Myrrha 60kg Sanguis Draxonis 20kg
Cortex Cinnamomi 20kg Herba Asari 60kg Borneolum Syntheticum 25kg
Camphora 30kg
Said medicine technology routinely adds conventional adjuvant and makes ointment.
Embodiment 3: liniment
Semen Strychni 35kg Radix Aconiti 35kg Radix Aconiti Kusnezoffii 85kg
Rhizoma Arisaematis 70kg Rhizoma Pinelliae 30kg Radix Kansui 20kg
Eupolyphaga Seu Steleophaga 70kg Holotrichia diomphalia Bates 40kg Rhizoma Paridis 30kg
Flos Daturae 30kg Semen Sinapis Albae 40kg Radix Notoginseng 40kg
Olibanum 30kg Myrrha 30kg Sanguis Draxonis 40kg
Cortex Cinnamomi 40kg Herba Asari 30kg Borneolum Syntheticum 15kg
Camphora 70kg
Said medicine technology routinely adds conventional adjuvant and makes liniment.
Embodiment 4: powder
Semen Strychni 60kg Radix Aconiti 60kg Radix Aconiti Kusnezoffii 60kg
Rhizoma Arisaematis 50kg Rhizoma Pinelliae 50kg Radix Kansui 30kg
Eupolyphaga Seu Steleophaga 50kg Holotrichia diomphalia Bates 30kg Rhizoma Paridis 50kg
Flos Daturae 50kg Semen Sinapis Albae 30kg Radix Notoginseng 30kg
Olibanum 45kg Myrrha 45kg Sanguis Draxonis 30kg
Cortex Cinnamomi 30kg Herba Asari 45kg Borneolum Syntheticum 20kg
Camphora 50kg Moschus 1.0kg
Said medicine technology routinely adds conventional adjuvant and makes powder.
Embodiment 5: spray
Semen Strychni 85kg Radix Aconiti 85kg Radix Aconiti Kusnezoffii 35kg
Rhizoma Arisaematis 30kg Rhizoma Pinelliae 70kg Radix Kansui 40kg
Eupolyphaga Seu Steleophaga 30kg Holotrichia diomphalia Bates 20kg Rhizoma Paridis 70kg
Flos Daturae 70kg Semen Sinapis Albae 20kg Radix Notoginseng 20kg
Olibanum 60kg Myrrha 60kg Sanguis Draxonis 20kg
Cortex Cinnamomi 20kg Herba Asari 60kg Borneolum Syntheticum 25kg
Camphora 30kg Moschus 0.7kg
Said medicine technology routinely adds conventional adjuvant and makes spray.
Embodiment 6: emplastrum
Semen Strychni 35kg Radix Aconiti 35kg Radix Aconiti Kusnezoffii 85kg
Rhizoma Arisaematis 70kg Rhizoma Pinelliae 30kg Radix Kansui 20kg
Eupolyphaga Seu Steleophaga 70kg Holotrichia diomphalia Bates 40kg Rhizoma Paridis 30kg
Flos Daturae 30kg Semen Sinapis Albae 40kg Radix Notoginseng 40kg
Olibanum 30kg Myrrha 30kg Sanguis Draxonis 40kg
Cortex Cinnamomi 40kg Herba Asari 30kg Borneolum Syntheticum 15kg
Camphora 70kg Moschus 1.3kg
Said medicine technology routinely adds conventional adjuvant and makes emplastrum.
Embodiment 7: spray
(life) Semen Strychni 60kg (life) Radix Aconiti 60kg (life) Radix Aconiti Kusnezoffii 60kg
(life) Rhizoma Arisaematis 50kg (life) Rhizoma Pinelliae 50kg (life) Radix Kansui 30kg
Eupolyphaga Seu Steleophaga 50kg Holotrichia diomphalia Bates 30kg Rhizoma Paridis 50kg
Flos Daturae 50kg (life) Semen Sinapis Albae 30kg Radix Notoginseng powder 30kg
(life) Olibanum 45kg (life) Myrrha 45kg Sanguis Draxonis 30kg
Cortex Cinnamomi 30kg Herba Asari 45kg Borneolum Syntheticum 20kg
Camphora 50kg
Said medicine technology routinely adds conventional adjuvant and makes ointment.
Embodiment 8: powder
(life) Semen Strychni 60kg (life) Radix Aconiti 60kg (life) Radix Aconiti Kusnezoffii 60kg
(life) Rhizoma Arisaematis 50kg (life) Rhizoma Pinelliae 50kg (life) Radix Kansui 30kg
Eupolyphaga Seu Steleophaga 50kg Holotrichia diomphalia Bates 30kg Rhizoma Paridis 50kg
Flos Daturae 50kg (life) Semen Sinapis Albae 30kg Radix Notoginseng powder 30kg
(life) Olibanum 45kg (life) Myrrha 45kg Sanguis Draxonis 30kg
Cortex Cinnamomi 30kg Herba Asari 45kg Borneolum Syntheticum 20kg
Camphora 50kg Moschus 1.0kg
Said medicine technology routinely adds conventional adjuvant and makes powder.
Claims (10)
1, a kind of pharmaceutical composition for the treatment of the nerve compression that hyperosteogeny and hyperosteogeny cause is characterized in that the crude drug of this pharmaceutical composition consists of:
Semen Strychni 30-90 weight portion Radix Aconiti 30-90 weight portion
Radix Aconiti Kusnezoffii 30-90 weight portion Rhizoma Arisaematis 25-75 weight portion
Rhizoma Pinelliae 25-75 weight portion Radix Kansui 15-45 weight portion
Eupolyphaga Seu Steleophaga 25-75 weight portion Holotrichia diomphalia Bates 15-45 weight portion
Rhizoma Paridis 25-75 weight portion Flos Daturae 25-75 weight portion
Semen Sinapis Albae 15-45 weight portion Radix Notoginseng 15-45 weight portion
Olibanum 25-65 weight portion Myrrha 25-65 weight portion
Sanguis Draxonis 15-45 weight portion Cortex Cinnamomi 15-45 weight portion
Herba Asari 25-65 weight portion Borneolum Syntheticum 10-30 weight portion
Camphora 25-75 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Semen Strychni 60 weight portion Radix Aconitis 60 weight portion Radix Aconiti Kusnezoffii 60 weight portions
The Rhizoma Arisaematis 50 weight portion Rhizoma Pinelliaes 50 weight portion Radix Kansuis 30 weight portions
Eupolyphaga Seu Steleophaga 50 weight portion Holotrichia diomphalia Batess 30 weight portion Rhizoma Paridis 50 weight portions
Flos Daturae 50 weight portion Semen Sinapis Albaes 30 weight portion Radix Notoginseng 30 weight portions
Olibanum 45 weight portion Myrrhas 45 weight portion Sanguis Draxonis 30 weight portions
Cortex Cinnamomi 30 weight portion Herba Asaris 45 weight portion Borneolum Syntheticums 20 weight portions
Camphora 50 weight portions.
3, pharmaceutical composition as claimed in claim 1 or 2, the crude drug that it is characterized in that this pharmaceutical composition adds Moschus 0.5-1.5 weight portion, preferred 1.0 weight portions, 0.7 weight portion or 1.3 weight portions in forming.
4, pharmaceutical composition as claimed in claim 1 or 2, it is characterized in that described Semen Strychni is a Semen Strychni, Radix Aconiti is a Radix Aconiti, and Radix Aconiti Kusnezoffii is a Radix Aconiti Kusnezoffii, and Rhizoma Arisaematis is a Rhizoma Arisaematis, Rhizoma Pinelliae Rhizoma Pinelliae, the Radix Kansui Radix Kansui of making a living, Semen Sinapis Albae is a Semen Sinapis Albae, Olibanum is an Olibanum, Myrrha is a Myrrha, and Radix Notoginseng is a Radix Notoginseng powder.
5, pharmaceutical composition as claimed in claim 1 or 2 is characterized in that this pharmaceutical composition adds pharmaceutically conventional adjuvant and makes emplastrum, ointment, liniment, powder or the spray of clinical acceptance.
6, pharmaceutical composition as claimed in claim 3 is characterized in that this pharmaceutical composition adds pharmaceutically conventional adjuvant and makes emplastrum, ointment, liniment, powder or the spray of clinical acceptance.
7, pharmaceutical composition as claimed in claim 4 is characterized in that this pharmaceutical composition adds pharmaceutically conventional adjuvant and makes emplastrum, ointment, liniment, powder or the spray of clinical acceptance.
8, the application of pharmaceutical composition as claimed in claim 1 or 2 in the medicine of the nerve compression that preparation treatment hyperosteogeny and hyperosteogeny cause.
9, the application of pharmaceutical composition as claimed in claim 3 in the medicine of the nerve compression that preparation treatment hyperosteogeny and hyperosteogeny cause.
10, the application of pharmaceutical composition as claimed in claim 4 in the medicine of the nerve compression that preparation treatment hyperosteogeny and hyperosteogeny cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101056988A CN101569706A (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101056988A CN101569706A (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101569706A true CN101569706A (en) | 2009-11-04 |
Family
ID=41229275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101056988A Pending CN101569706A (en) | 2008-05-04 | 2008-05-04 | Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101569706A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274363A (en) * | 2010-06-08 | 2011-12-14 | 金龙汉 | Pharmaceutical composition for treating osteoproliferation and preparation method thereof |
| CN103623162A (en) * | 2013-12-03 | 2014-03-12 | 蚌埠市宫氏太极医疗用品科技有限公司 | Traumatic injury treatment paste and preparation method thereof |
| CN111202791A (en) * | 2018-11-06 | 2020-05-29 | 师海全 | External ointment for treating burn, scald and wound of shiny-leaved yellowhorn bedsore and preparation method thereof |
-
2008
- 2008-05-04 CN CNA2008101056988A patent/CN101569706A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274363A (en) * | 2010-06-08 | 2011-12-14 | 金龙汉 | Pharmaceutical composition for treating osteoproliferation and preparation method thereof |
| CN102274363B (en) * | 2010-06-08 | 2013-04-24 | 金龙汉 | Pharmaceutical composition for treating osteoproliferation and preparation method thereof |
| CN103623162A (en) * | 2013-12-03 | 2014-03-12 | 蚌埠市宫氏太极医疗用品科技有限公司 | Traumatic injury treatment paste and preparation method thereof |
| CN103623162B (en) * | 2013-12-03 | 2016-05-04 | 蚌埠市宫氏太极医疗用品科技有限公司 | A kind of bone god cream and preparation method thereof |
| CN111202791A (en) * | 2018-11-06 | 2020-05-29 | 师海全 | External ointment for treating burn, scald and wound of shiny-leaved yellowhorn bedsore and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071055B (en) | Externally applied traditional Chinese medicine composition for curing diseases of orthopedics and traumatology and preparation method of externally applied traditional Chinese medicine | |
| CN102670979B (en) | Osteopathic medicinal wine for treating rheumatism and preparation process thereof | |
| CN104922205A (en) | Traditional Chinese medicine formula for treating lumbar disc herniation | |
| CN101569706A (en) | Pharmaceutical composition for treating hyperosteogeny and neurothlipsis caused by hyperosteogeny | |
| CN101810834A (en) | Chinese medicinal composition for treating paralysis and preparation method thereof | |
| CN100548343C (en) | A kind of medicine and preparation technology thereof who treats Feng Han Shi Paralysis, hyperosteogeny, intervertebral disk hernia | |
| CN104873945B (en) | A kind of Chinese medicine composition for the treatment of rheumarthrosis and preparation method thereof | |
| CN102920927B (en) | Chinese medicinal composition for treating fresh traumatic paraplegia | |
| CN103007144A (en) | Medicinal composition for treating bone traumas | |
| CN103638138B (en) | The Chinese medicine for outer use for the treatment of achilles bursitis | |
| CN105456745A (en) | Medicine composition for treating sequela of apoplexy | |
| CN105395772A (en) | Traditional Chinese medicine composition for treating fractures and pains in neck, shoulder, low back and leg | |
| CN104147128A (en) | Traditional Chinese medicine preparation for treating refractory arthralgia | |
| CN1615968A (en) | Chinese medicine preparation bone setting powder for treating traumatic injury | |
| CN101502604B (en) | Chinese herbal medicine preparation for treating rheumatism | |
| CN103055216B (en) | Three-original ecology tracing conjugate bonesetting reduction health traditional Chinese medicine preparation and preparation method thereof | |
| CN201492625U (en) | Multifunctional combined hot compress tractor | |
| CN103083602B (en) | Externally used pharmaceutical composition for treating lumbar disease | |
| Ostrom | Massage and the original Swedish movements | |
| CN102343066B (en) | Medicinal composition for treating hyperosteogeny and preparation method thereof | |
| Shaikh et al. | THERAPEUTIC IMPORTANCE OF ABHYANGA IN TODAYS ERA | |
| CN106309992A (en) | Traditional Chinese medicine composition for treating osteoproliferation | |
| Sun et al. | The review of clinical application of X-shaped balance acupuncture therapy for joint pain and activity disorder | |
| CN108888740A (en) | A kind of bone strengthening ostalgia emplastrum and preparation method thereof | |
| Zhu et al. | The Traditional Chinese Bonesetting Manipulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091104 |